Alector Inc
Research Alector Inc (ALEC) on Bullrun: market cap USD 263.51M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALEC
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 263.51M
- Financial periodQ2 2026
- RevenueUSD 3.32M
- Net income-USD 22.99M
- Free cash flow-USD 34.25M
Valuation Snapshot
latest market cap is USD 263.51M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 21.05M | -USD 143.00M | -USD 184.07M | n/a | -1.39 | USD 65.80M | USD 9.69M | USD 30.65M |
| FY2024 | USD 100.56M | -USD 119.00M | -USD 231.16M | n/a | -1.23 | USD 33.02M | USD 9.39M | USD 126.80M |
| FY2023 | USD 97.06M | -USD 130.00M | -USD 186.54M | n/a | -1.56 | USD 74.56M | USD 0 | USD 134.16M |
| FY2022 | USD 133.62M | -USD 133.31M | -USD 24.45M | n/a | -1.62 | USD 154.32M | USD 45.54M | USD 214.44M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 263.51M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 172.17M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 187.27M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 671.41M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 763.33M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.69B | n/a | n/a | n/a |
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alector Inc's market cap?
Alector Inc's market capitalization is USD 263.51M.
What does Alector Inc do?
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.